Company intelligence
As of September 23, 2026, Enveda Biosciences was last valued at ~$2B (September 2026 Series E) and has raised at least $311M in equity across 1 sourced funding round.
Enveda Biosciences is a Boulder, Colorado-based clinical-stage biotechnology company that uses artificial intelligence to discover medicines from naturally occurring molecules.[1] Enveda has three drug candidates in human testing for immune diseases and obesity, according to BioPharma Dive.[2]
Is something wrong on this page?
| Date | Round | Amount | Valuation | Lead investors | Source |
|---|---|---|---|---|---|
| Sep 23, 2026 | Series E | $311M | ~$2Bpost-money | Tech Startups |
Equity only. “Equity raised” above sums the rounds with a dated, linked source; rumored rounds, tender offers and secondary sales are listed but not counted, and debt financing is listed separately.
The company raised a $130 million Series C led by Kinnevik and FPV in 2024, later extended to $150 million when Sanofi joined, and a $150 million Series D led by Premji Invest in September 2025.[3] In September 2026 Enveda raised a $311 million Series E led by Catalio Capital Management, with 16 other backers including Surveyor Capital.[2] The company says its total funding since inception is more than $845 million, and the Series E will fund its three clinical-stage candidates, additional therapies and its discovery platform.[1]
In September 2026 Enveda raised a $311 million Series E led by Catalio Capital Management, with 16 other backers including Surveyor Capital.[2]
Enveda Biosciences raised a $130 million Series C led by Kinnevik and FPV in 2024, later extended to $150 million when Sanofi joined, and a $150 million Series D led by Premji Invest in September 2025.[3]
Founded in 2019 and led by founder and CEO Viswa Colluru, it uses AI to identify molecules in plants and microbes, predict their structure and function, and rank them by drug potential.[3]
Enveda Biosciences is a Boulder, Colorado-based clinical-stage biotechnology company that uses artificial intelligence to discover medicines from naturally occurring molecules.[1]
Enveda Biosciences was last valued at ~$2B in its September 2026 Series E, according to Tech Startups (September 23, 2026).
Enveda Biosciences was founded in 2019 and is headquartered in Boulder, Colorado, USA, according to Wikidata.
Figures are labelled Reported (a source states it), Estimated, Derived (computed from other facts) or Rumored (in talks / unconfirmed). Rumors never replace a confirmed figure. Each figure keeps its own as-of date; history is preserved rather than overwritten.